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Abstract 
Progress in genomics and proteomics attended to the door for better understanding the 
recent rapid expanding complex research field of metabolomics. This trend in biomedical 
research increasingly focuses to the development of patient-specific therapeutic approaches 
with  higher  efficiency  and  sustainability.  Simultaneously  undesired  adverse  reactions  are 
avoided. In parallel, the development of molecules for molecular imaging is required not only 
for the imaging of morphological structures but also for the imaging of metabolic processes 
like the aberrant expression of the cysteine protease cathepsin B (CtsB) gene and the activity 
of the resulting product associated with metastasis and invasiveness of malign tumors. Finally 
the objective is to merge imaging and therapy at the same level. The design of molecules which 
fulfil these responsibilities is pivotal and requires proper chemical methodologies. In this 
context our modified solid phase peptide chemistry using temperature shifts during synthesis 
is considered as an appropriate technology. We generated highly variable conjugates which 
consist of molecules useful as diagnostically and therapeutically active molecules. As an ex-
ample the modular PNA products with the complementary sequence to the CtsB mRNA and 
additionally with a cathepsin B cleavage site had been prepared as functional modules for 
distinction of cell lines with different CtsB gene expression. After ligation to the modular 
peptide-based BioShuttle carrier, which was utilized to facilitate the delivery of the functional 
modules into the cells’ cytoplasm, the modules were scrutinized. 
Key words: Click Chemistry; Diels Alder Reactioninverse (DARinv); Fluorescence Imaging; Peptide 
Nucleic Acid (PNA); PNA building block functionalization 
Introduction 
A  search  for  the  very  first  documentations  of 
peptide nucleic acids (PNA) led to Miller’s and Urey’s 
experiments in the year 1953. They verified the hy-
pothesis of the appearance of organic molecules under 
reducing atmospheric conditions [1]. The PNA’s role 
as  a  pivotal  prebiotic  molecule  in  the  RNA  world 
which acts as a template for the polymerization of the 
complementary nucleotide phosphoroimidazoles was 
postulated [2-6]. The focus lies on Nielsen’s successful 
pioneering work in the PNA syntheses [7]. Contribu-
tions  were  made  by  the  introduction  of  the  Mer-
riefield’s  solide  phase  peptide  synthesis  [8]  and 
Carpino’s protecting group methodologies [9]. Addi-
tionally  further  parameters  like  the  micro-
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wave-assistance  [10,  11],  the  choice  of  the  solvents 
[12], the manual and automated procedures as well as 
the selection of resins and linkers [13, 14] ameliorated 
the SPPS methodology concerning the yields, purity, 
and reaction times are comprehensively documented 
by Martinez [15]. 
All this enabled the use of PNAs useful in many 
ways, for instance as antisense molecules in pro- as 
well as in eukaryotic organisms [16, 17], and as triplex 
forming  oligonucleotides  (TFO)  for  antigenic  strate-
gies [18-20]. From this point of view the use as thera-
peutic  and  diagnostic  agents  was  documented  [21]. 
Further, PNAs  have applications  in analysis  of bio-
sensor  chips  for  identification  of  nucleic  acids  [22]. 
The structural and the physico-chemical properties of 
PNAs as well as the different synthesis methodologies 
are well documented [23-30]. They reveal similarities 
to  the  native  nucleic  acids  whose  phospho-ribose 
backbone  is  substituted  by  a  backbone  of 
poly-2-aminoaethyl  glycine  with  nucleobases  con-
nected via an acetate linker [31-34].  
The use of PNA molecules is not restricted to its 
role as a DNA derivative. Derivatizations permit fur-
ther functionalizations of the PNA polyamide back-
bone as demonstrated [35, 36]. Finally the nucleobases 
were substituted with functional molecules as reac-
tion partners for chemical reactions, for instance as a 
ligation  partner  in  the  “click-chemistry”  [37-40]. 
Manifold ligation reactions like the copper catalyzed 
alkine-azide cycloadditions introduced by Sharpless 
[41] are well reviewed by El-Sagheer and Brown [42]. 
Here for instance, we used as ligation technology the 
Diels  Alder  Reaction  with  inverse  electron  demand 
(DARinv) introduced by Lindsay [43] and comprehen-
sively investigated by Sauer [44] and Bertozzi [45, 46]. 
The potential of the DARinv is well documented, un-
doubted and underlines multifaceted applications in 
the  medical  science.  It  is  an  attractive  platform  for 
active agents in therapy [47-50] as well as for imaging 
components in diagnostics [51, 52]. The combination 
of different drugs and different diagnostic molecules 
in optimized ratios [52] allows the design of molecules 
ready to use for bi- tri- and multi-modal strategies. 
These can be considered as promising  molecules in 
the personalized medicine and in the increasing field 
of theranostics [53]. Our variant, a heat-assisted ap-
proach of the solid phase peptide synthesis is consid-
ered as an indispensable methodology which realizes 
a  proper  chemistry  of  PNA-based  backbones  func-
tionalized multifold with a great potential to contrib-
ute  to  the  diagnostics’  precision  and  to  the  better 
therapy’s success.  
We  tested  the  synthesized  PNAs  implemented 
into  the  drug  delivery  and  targeting  system  called 
BioShuttle [54] as functional modules for hybridiza-
tion in the cells with target sequences in the cathepsin 
B (CtsB) mRNA reacting in case of the existence of the 
activated CtsB enzyme in the cells [55]. After enzy-
matic cleavage in the cytoplasm the fluorescent dye 
Rhod110 is transported and detectable in the cell nu-
cleus. 
Chemical Procedures & Results 
PNA synthesis 
For  the  PNA  synthesis  of  the  sequences  (I) 
cagcgctgcag-C,  (II)  ctgcagcgctg-C,  and  (III) 
agcgctgagct-C (listed in the column D of Table 1) we 
used  a  manual  synthesizer,  PetiSyzer®  from  HiPep 
Laboratories,  Kyoto,  Japan.  On  this  instrument  we 
performed  low  cost  simultaneous  synthesis  in  dis-
posable polypropylene reactors. An assembly of five 
disposable reactors is connected to a polytetrafluoro-
ethylene  tube  (PTFE)  manifold  via  PTFE  two-way 
valves and are fixed on to a rack that can be shaken by 
a  vortex-like  mixer.  The  five  reactors  make  contact 
with an aluminium block whose temperature is con-
trolled by either an electric heater or cooled by the 
circulation of chilled liquid. In peptide synthesis it is 
known  that  elevated  temperatures  in  the  coupling 
reaction can overcome some coupling difficulties and 
shorten the coupling time. However it is also known 
that Fmoc-removal with piperidine at elevated tem-
peratures results in  racemization. Thus temperature 
control is required for such reactions. For the present 
PNA synthesis we intended to minimize aggregation 
and  sterical  hindrance  by  raising  the  temperature 
during the coupling time as it is known from peptide 
synthesis [56]. We used 9-fluorenylmethoxycarbonyl 
chloride  (Fmoc)-building  blocks  with  blocked  side 
chains of Adenine A, Cytosine C, and Guanine G by 
benzhydroxylcarbonyl (Bhoc) groups. The syntheses 
were  performed  in  an  2  µmol  scale  on  a 
H-Cys(Trt)-HMPB-ChemMatrix®  resin  loading  0.19 
mmol/g. In the first step the Fmoc-group was cleaved 
with 20% piperidine in dimethylformamide (DMF) for 
5 min at 20°C. After that, the resin was washed 5 times 
with DMF. For the coupling reaction the temperature 
was  raised  to  80°C  and  the  coupling  reaction  was 
performed  with  2-(1H-7-azabenzotriazol-1-yl)- 
1,1,3,3-tetramethyl  uronium  hexafluorophosphate 
(HATU)  and  diisopropylethylamine  (DIPEA)  for  40 
min. After the coupling all free amino groups were 
capped with acetic acid anhydride in DMF and the 
resin  was  washed  with  DMF.  Before  the  next 
Fmoc-deprotection step the reaction vessel was cooled 
to 20°C and the resin was treated with 20% piperidine 




was  a  cleavage  of  the  N-terminal  protecting  group 
with piperidine. 
A small sample of each PNA was cleaved with 
TFA  (90%)  and  scavanger  thriethylsilan/water 
(2.5%/2.5%) for 2.5 h at room temperature. The PNA 
was  precipitated  in  ether  and  lyophilized.  Analysis 
was carried out with HPLC and MS. By using differ-
ent  temperatures  (20°C  for  Fmoc-protection  (avoid 
racemization) and 80°C for the coupling reaction we 
could improve coupling efficiency compared to use of 
elevated temperature for the whole synthesis. 
Table 1. The schematic structure of the CtsB-BioShuttle (upper part) accentuates the modular construction which consists of the 
following functional units: CPP module (red) is responsible for the passage across cell membranes (the amino acid sequence is 
shown in the column F). The PNA module (yellow) harbours the sequences for the hybridization (column D, line 1 – antisense; line 
2 – sense; line 3 – random) with the target-sequence inside of the CtsB mRNA’s Exon I. After the enzymatic cleavage  (red) of 
the disulfide bridge (column E) inside of the cytosol, the CtsB cleavage module (column C, highlighted in grey)  covalently 
coupled to the NLS module (column B, red/blue) is cut. This in turn is connected to the Rhod110 (column A) fluorescent dye as a 




PNA I - cag cgc tgc ag-C 
 
Figure 1. shows the structural formula of the PNA I (upper part). The lower part demonstrates the graphs of HPLC (left) 






Found mass: 3106.2; (M-2H)2+ 1553.21; (M+3H)3+ 1035.3 
Exact mass: 3106.19 (Mol. Wt.: 3107.98);  
m/e:  3107.19  (100.0%),  3108.19  (94.4%),  3106.19  (74.8%),  3109.19  (29.6%),  3109.20  (28.7%),  3107.18  (18.5%),  
3110.20 (14.5%), 3110.19 (14.0%), 3111.20 (6.9%), 3108.18 (5.8%), 3111.19 (4.6%), 3109.18 (4.0%), 3112.20 (2.3%), 
3108.20 (1.7%), 3110.18 (1.5%), 3112.19 (1.1%) 






PNA II - ctg cag cgc tg-C 
 
Figure 2. shows the structural formula of the PNA II (upper part). The lower part demonstrates the graphs of HPLC (left) 
and mass (right). 
 
C120H152N64O36S: 
Found mass: 3097.0; (M-2H)2+ 1548.5; (M+3H)3+ 1032.3 
Exact mass: 3097.18; (Mol. Wt.: 3098.96) 
m/e: 3098.18 (100.0%), 3099.18 (95.9%), 3097.18 (75.2%), 3100.19 (28.8%), 3100.18 (24.9%), 3098.17 (18.4%), 3101.19 
(14.5%), 3101.18 (13.9%), 3100.17 (8.3%), 3102.19 (7.1%), 3099.17 (5.6%), 3102.18 (3.9%), 3103.19 (1.9%), 3101.17 
(1.6%), 3103.18 (1.5%), 3102.17 (1.0%) 
C, 46.51; H, 4.94; N, 28.93; O, 18.59; S, 1.03 




PNA III – agc gct gag ct-C 
 
Figure 3. shows the structural formula of the PNA III (upper part). The lower part demonstrates the graphs of HPLC (left) 
and mass (right). 
 
C121H152N66O35S; 
Found mass: 3123.2; (M-2H)2+ 1561.6; (M+3H)3+ 1040.6 
Exact mass: 3121.19; Mol. Wt.: 3122.99 
m/e: 3122.19 (100.0%), 3123.19 (94.7%), 3121.19 (74.2%), 3124.19 (29.7%), 3124.20 (29.1%), 3122.18 (18.1%), 3125.20 
(14.7%), 3125.19 (14.0%), 3126.20 (7.1%), 3123.18 (5.7%), 3126.19 (4.6%), 3124.18 (3.9%), 3127.20 (2.4%), 3123.20 
(1.7%), 3125.18 (1.6%), 3127.19 (1.1%) 





The  peptides  C-RQIKIWFQNRRMKWKK 
[pAnt43-58],  VKRKKP-GFGRK-  cagcgctgcag-C, 
VKRKKP-GFGRK-ctgcagcgctg-C,  and  VKRKKP- 
GFGRK-agcgctgagct-C  were  synthesized  in  an 
automated  multiple  synthesizer  Syro  II  (MultiSyn 
Tech,  Germany)  using  Fmoc  chemistry  under 
atmospheric  conditions  at  room  temperature  using 
the  Fmoc-Lys(Boc)-HMPB-ChemMatrix®  resin 
loading  0.50  mmol/g.  For  amino  acid  coupling  a 
fivefold excess of the Fmoc-protected amino acid was 
activated  in  situ  with  5  equivalents 
2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate  (HBTU)  and  DIPEA  (0.5M)  in 
DMF. The coupling time was 40 min. The Fmoc-group 
was cleaved with piperidine (20%) in DMF for 3 min 
and 10 min. After each step the resin was washed 5 
times with DMF. 
The Rhodamine 110 marker was inserted into the 
peptide by a manual coupling procedure. A threefold 
excess  of  this  marker  was  activated  in  situ  with  3 
equivalents  HATU  and  2  equivalents  DIPEA  and 
added to the resin bound peptide for one hour reac-
tion  time.  Afterwards  the  resin  was  washed  three 
times  with  DMF,  dichloromethane  (DCM)  and  iso-
propanol  and  dried.  The  following  cleavage  of  the 
peptide from the resin and of the side chain protecting 
groups was performed with trifluoroacetic acid (TFA) 
(90%)  and  as  scavenger  triethylsilan/water 
(2.5%/2.5%) for 2.5 h at room temperature was used. 
 
 




Synthesis of the pAnt43-58 – cell penetrating peptide (CPP) 
 
Figure 4. shows the structural formula of the pAnt43-58 (upper part). The lower part demonstrates the graphs of HPLC 
(left) and mass (right). 
C107H174N35O21S2; 
Found mass:2349.305; 
Exact Mass: 2349.3; Mol. Wt.: 2235.77 
m/e: 2350.30 (100.0%), 2351.31 (77.8%), 2353.31 (43.9%), 2354.31 (19.8%), 2355.26 (2.4%), 2356.31 (0.7%), 2357.31 





Figure 5. shows exemplarily the HPLC and MS plots of the CtsB-BioShuttle construct 1 (shown in Table 1) containing the 
antisense PNA I after synthesis. 
 
Found mass: 
Exact mass: MW Cal: 6006.21 1501.37 (M+4H)
4+; 1201.39 (M+5H)
5+; 1001.28 (M+6H)





Purification of pAnt43-58 and Rhoda-
mine-peptide-PNA conjugates 
The crude material was purified by preparative 
HPLC on a Kromasil 100–10C 18 µm reverse phase 
column  (30´  250mm)  using  an  eluent  of  0.1%  tri-
fluoroacetic acid in water (A) and 80% acetonitrile in 
water (B). The peptide was eluted with a successive 
linear gradient of 10% B to 80% B in 30 min at a flow 
rate of 23 ml/min. The fractions containing the puri-
fied protein were lyophilized. The purified material 
was characterized with analytical HPLC and matrix 
assisted  laser  desorption  mass  spectrometry 
(MALDI-MS) (Figure 1 - 5Figure 1). 
Ligation via disulfide bridge formation 
The  disulfide  bridge  between  the  N-terminal 
cysteine  of  pAnt43-58  and  the  N-terminal  cysteine 
residue of the NLS was achieved by the activation of 
one  cysteine  using  2,2’-dithiopyridine  and  the  sub-
sequent coupling to the cysteine of the other module. 
The  coupling  reaction  was  carried  out  in  an  etha-
nol / water buffer at 60°C.  
The  individual  components  and  the  complete 
modules  were  validated  using  LCMS  (Shimadzu 
LC-10 and LCQ electrospray, Finnigan-Mat, (Thermo 
Fischer Scientific GmbH, Bremen, Germany). The pu-
rity levels were generally >90%.  
After ligation the reaction products were tested 
in the following cell study; the ultimate conjugates are 
listed Table 1. 
Cell culture & CtsB-BioShuttle 
FFM-measurements 
In  order  to  characterize  the  CtsB-BioShuttle 
conjugates we used HeLa [57, 58] and MDA-MB-231 
[59, 60], human cell lines which are characterized by 
their different CtsB expression and activity of the gene 
product.  CtsB  considered  as  a  genetic  marker  is 
strongly expressed during proteolysis’ and apoptosis’ 
processes  [61-63].  Therefore  the  CtsB  mRNA  was 
chosen as a target for a fluorescent imaging test of our 
CtsB-BioShuttle constructs. 
In GenBank with the accession number M14221 
the  human  cathepsin  B  mRNA  sequence  was 
searched.  This  sequence  describes  the  total  CtsB 
mRNA.  
The  bases  sequences  of  the  three  investigated 
PNAs are represented as follows:  
The PNA I is the corresponding antisense mol-
ecule  and  possesses  the  antiparallel  complementary 
sequence of the CtsB mRNA Exon I at the position 
70-80. As a control we synthesized the PNA II which 
is identical with the sequence of the CtsB mRNA at 
the end of the Exon I position 70-80 [64]. The PNA 
III’s sequence is randomized. 
The  MDA-MB-231  cell  line  was  cultivated  in 
Dulbeco’s  modified  Eagles  Medium  (DMEM)  (Invi-
trogen Life Technologies,  Carlsbad, USA) with 10% 
fetal calf serum and 1% Glutamine (Biochrom, Ger-
many). The HeLa cells were cultivated in RPMI 1640 
(GIBCO,  Invitrogen)  supplemented  with  10%  fetal 
Calf  serum.  All  cell  lines  were  cultivated  without 
phenol red and maintained at 37°C in 5% CO2 with 
high atmospheric humidity.  
24  hours  before  fluorescence  measurement 
studies  the  cells  were  washed  in  Hank’s  Balanced 
Salts  (PAN-Biotech,  Germany),  after  treatment  with 
trypsin/EDTA  solution  (0.5/0.2  %)  harvested  and 
suspended in fresh medium. Cell suspension (400 µl) 
were  transferred  to  chambers  of  the  Lab-Tek 
Chamber  Slides  (Nunc,  USA)  and  incubated  under 
identical  conditions  as  described  above.  For  meas-
urement studies the MDA-MB-231 cells were treated 
with the CtsB-BioShuttle conjugates PNA I, PNA II, 
and PNA III (final concentration 100 nM) for 1 h. Fi-
nally, the medium was removed and the cells were 
washed with Hank’s and fresh medium was added. 
The  HeLa  cells  were  treated  identically  with  the 
CtsB-BioShuttle PNA I variant (as a negative control). 
After 24 hours, the samples were measured as shown 
in Figure 6. 
Discussion and outlook 
Progresses in both, the genome - and in the in-
formatics  research  established  proteomics  and 
metabolomics and influenced the pharmaceutical re-
search  in  diagnostic  as  well  as  in  therapeutic  areas 
[65-70].  “Old  fashioned”  diagnostic  molecules  and 
drugs are highly effective but not sensitive enough, 
hamper the therapeutic success and result in discon-
tinuation of treatment. It is beyond controversy that 
these drugs, which represent the old paradigm “one 
size fits all”, is not really up-to-date anymore [71, 72]. 
The Blockbusters’ importance seems to approach 
perpetually its end, in parallel, the time for individual 
therapeutic interventions started  [73, 74]. The situa-
tion  changed  and  the  new  paradigm  delineates  the 
“patient  specific  medicine”  [75].  This  “personalized 
medicine” is based on the generation and application 
of the patient-specific drug [76, 77]. The development 
of such components  is deemed to be a global chal-
lenge for “Big  Pharma”. In consideration of  quality 
and  specificity  the  biotech  industry  seems  to  have 
advances in providing breakthrough products more 
efficiently  than  pharmaceutical  industrial  manufac-
turing [78]. The recombinant chemistry together with 




represent two methodologies to fulfil the demands of 
crucial  criteria  (high  quality  &  high  variability)  for 
biotechnology  products  [79]  and  the  synthesis  of 
molecules designed for the patient’s genetic disposi-
tion.  
Here we discuss a SPPS variant featuring these 
properties which is based on the classical solid phase 
strategy but focuses on the temperature as physical 
parameter. However, folding processes after peptide 
syntheses can hamper the prolongation of the peptide 
bond formation during the solid phase synthesis. 
Microwave heat assisted syntheses, however at 
elevated  reaction  temperature  resulted  in  increased 
racemization [80, 81]. We circumvented this drawback 
using a concept based on a personal synthesizer, used 
for  peptide  synthesis  and  also  for  organic  chemical 
syntheses that involves heating, cooling and filtration 
procedures [82]. A microwave methodology provid-
ing synthesis conditions avoiding racemization is still 
under  investigation  by  the  Nokihara  group,  HiPep 
Laboratories, Kyoto (unpublished data).  
The  temperature  is  assumed  to  be  the  critical 
parameter in limiting the peptide synthesis as docu-
mented  in  1988  by  Merrifield  [83].  A  heat-induced 
unfolding of peptide chains can be understood as an 
initial  point  for  the  successful  construction  of  large 
proteins, shown by the Dolphin group [56]. Here we 
studied this methodology in the solid phase synthesis 
of peptide nucleic acids as an initial step for the entry 
into “personalized medicine” in oncology using ex-
emplarily the cathepsin B gene (CtsB) and the corre-
sponding mRNA as molecular target. The SPPS, the 
attachment of a fluorescence dye and the following 
ligation of the modules by disulfide formation result 
in  the  final  CtsB-BioShuttle  conjugate  designed  for 
fluorescence imaging in the selected cell lines. HeLa 
cells were used as a control and the imaging of the 
CtsB  mRNA  was  documented  [55].  Here  we  con-
firmed the data of the non-invasive HeLa cervix car-
cinoma  and  the  invasive  MDA-MB-231  the  breast 
cancer  cell  lines  differentially  expressing  the  CtsB 
(Figure 6). The CtsB-BioShuttle on MDA-MB-231 re-
sulted in strong signal using the construct with the 
complementary PNA I. This would be the direct way 
to detect tumor cells and treat with patient specific 
PNA at the same time. Insistently, the complexity of 
the pharmaceutical research and in biotechnology, the 
dedicated chemical methodologies like the SPPS hold 
a  key  role  in  the  development  of  patient-specific 




Figure 6. The figure shows FFM-measurement pictures the of the cell lines: MDA-MB-231 cells 24 hours after treatment 
(final concentration 100 nM) with the CtsB-BioShuttle conjugates PNA I, PNA II and PNA III, and HeLa control cells (right 
picture) treated with the PNA I (antisense). The fluorescence signals can be observed inside of both lines and indicate an 
uptake of all tested CtsB-BioShuttle conjugates. Whereas the fluorescence signal intensity inside of the cytoplasm of the 
MDA-MB-231 cells treated with PNA III (random) is hardly visible related to the signal intensities inside of the cytosol of 
MDA-MB-231 cells which are treated with PNA I and PNA II. Solely in the nuclei of the MDA-MB-231 cells treated with the 
PNA I clear morphologic structures with high fluorescence intensities are recognizable. The HeLa control cells treated with 
the PNA I (antisense) did not show fluorescence signals. 
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